Recent oncology breakthroughs include bispecific antibody-drug conjugates and novel oncolytic virus-immunotherapy combinations poised to expand treatment horizons. Radiance Biopharma secured a potential $1.165 billion deal for a c-MET/EGFR bispecific nano ADC targeting solid tumors. Simultaneously, research integrating oncolytic viruses with immune checkpoint therapies shows promise in overcoming tumor resistance mechanisms. These advancements underscore an evolving therapeutic landscape leveraging multi-targeted and immune modulating strategies to tackle challenging malignancies.